<DOC>
	<DOCNO>NCT02385019</DOCNO>
	<brief_summary>Phase 1/2 clinical study treatment steroid-refractory chronic graft versus host disease allogeneic transplant hematopoietic progenitor donor CliniMACS-selected regulatory T cell</brief_summary>
	<brief_title>A Phase 1/2 Trial Donor Regulatory T-cells Steroid-Refractory Chronic Graft-versus-Host-Disease</brief_title>
	<detailed_description>Phase 1/2 clinical study evaluate safety ( Phase 1 ) preliminary efficacy ( Phase 2 ) donor regulatory T cell patient steroid-refractory chronic graft versus host disease ( GVHD ) allogeneic hematopoietic stem cell transplantation ( HSCT ) . Patients must persistent sign symptom despite use prednisone equivalent ≥ 0.25 mg/kg/day ( 0.5 mg/kg every day ) , least 4 week without complete resolution sign symptom . Occasional patient require low dos prednisone eligible associate immunosuppressive drug . Phase 1 clinical trial include group 5 patient sequentially treat : 0.5 x 10ˆ6 , 1.0 x 10ˆ6 , 2-3 x 10ˆ6 donor Treg/kg . Phase 2 clinical trial include another 5 10 patient treated MTD . Donor Treg select follow sequential step : 1 . - negative depletion CD8 CD19 cell 2 . - positive selection CD25 cell</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>1 . Patients must persistent sign symptom despite use prednisone equivalent ≥ 0.25 mg/kg/day ( 0.5 mg/kg every day ) , least 4 week without complete resolution sign symptom . Occasional patient require low dos prednisone eligible associate immunosuppressive drug . 2 . Stable immunosuppressive medication 4 week prior initiation treatment 3 . PS 02 ECOG 4 . Adequate liver , kidney , lung hematopoietic system function 1 . Pediatric patient 2 . Pregnant woman 3 . Ongoing prednisone requirement &gt; 1 mg/kg/day ( equivalent ) 4 . Concurrent use calcineurininhibitor plus sirolimus ( either agent alone acceptable ) 5 . New immunosuppressive medication 4 week prior 6 . Extracorporeal Photopheresis rituximab therapy 4 week prior 7 . Exposure Tcell IL2 target medication ( e.g . ATG , alemtuzumab , basiliximab , denileukin diftitox ) within 100 day prior 8 . Donor lymphocyte infusion within 100 day prior 9 . Active malignant relapse 10 . Active uncontrolled infection 11 . HIVinfected patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Allogeneic hematopoietic stem cell transplantation</keyword>
	<keyword>Graft v host disease</keyword>
	<keyword>Regulatory T cell</keyword>
</DOC>